Twenty-one coronary artery disease patients received either placebo treatment or intracoronary bolus infusion of 40 μg/kg of GM-CSF, followed by a two week period of subcutaneous injections of 10 μg/kg GM-CSF every other day [64]. Here, CSF2 is linked to coronary artery disorder.